Company profile: Rain Oncology
1.1 - Company Overview
Company description
- Provider of precision oncology therapies targeting oncogenic drivers, developing milademetan, an oral small molecule inhibitor of the p53-MDM2 complex for various cancers. Clinical programs include MANTRA (Phase 3 in dedifferentiated liposarcoma), MANTRA-2 (Phase 2 in TP53 wildtype/MDM2-amplified solid tumors), and MANTRA-4 (Phase 1/2 with atezolizumab in CDKN2A loss, TP53 wildtype tumors).
Products and services
- MANTRA: A Phase 3 clinical trial evaluating the efficacy and safety of milademetan in patients with dedifferentiated liposarcoma who have progressed on prior therapy
- Milademetan: An investigational, oral small molecule inhibitor targeting the p53-MDM2 complex, engineered to treat various cancers including liposarcomas and other solid tumors under active clinical evaluation
- MANTRA-2: A Phase 2 clinical trial investigating milademetan in patients with relapsed or refractory advanced/metastatic TP53 wildtype, MDM2-amplified solid tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rain Oncology
Blue Earth Diagnostics
HQ: United Kingdom
Website
- Description: Provider of molecular PET imaging agents and technologies for cancer diagnosis, developing and commercialising radiopharmaceuticals addressing high unmet medical needs. Offerings include Axumin (fluciclovine F 18) for detecting recurrent prostate cancer, POSLUMA (flotufolastat F 18) Injection for detecting prostate cancer, FAP-targeted PET technology for multiple solid tumors, and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blue Earth Diagnostics company profile →
OncoResponse
HQ: United States
Website
- Description: Provider of immuno-oncology therapies leveraging human immune responses, with a proprietary human-antibody discovery platform sourcing antibodies from elite responder patients; OR2805 targeting M2-like tumor-associated macrophages; collaboration with MD Anderson; and a preclinical pipeline of monoclonal antibodies addressing immunosuppression in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoResponse company profile →
Point Biopharma
HQ: United States
Website
- Description: Provider of radioligand therapies for cancer, with a globally focused platform for the clinical development and commercialization of radioligands. Combines a portfolio of radiopharmaceutical assets with a seasoned management team and expertise in radioisotopes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Point Biopharma company profile →
Arthrosi Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology drug discovery and development, focused on AR882, a uricosuric therapy in development for gout to lower serum urate levels, reduce flares, and resolve tophi, with efficacy and safety demonstrated in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arthrosi Therapeutics company profile →
Orionis Biosciences
HQ: United States
Website
- Description: Provider of biotechnology platforms for healthcare innovation, including the A-Kine platform for engineering cytokines with targeted cell selectivity and controlled activity for cancer immunotherapy, and the Allo-Glue platform for discovering and designing small molecule molecular glues to modulate or degrade disease targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orionis Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rain Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rain Oncology
2.2 - Growth funds investing in similar companies to Rain Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rain Oncology
4.2 - Public trading comparable groups for Rain Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →